House Dust Mite Allergy Evidence-Based Management-Separating Truth from Fiction Webinar

May 9, 2019

Patients with house dust mite allergy and asthma comprise a major number of patients cared for by the allergist. This activity will review the latest published data on house dust mite management and break many of the myths of “what works best” for our patients. 

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 1 AMA PRA Category I Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement
This activity was supported by an independent educational grant from ALK-Abelló, Inc.

 

Target Audience

Allergists, allied health and other allergy practitioners.

Learning Objectives

  • Describe how effective indoor dust mite reduction is in improving allergy and asthma control
  • Summarize the efficacy and value of pharmacologic agents in decreasing symptoms related to house dust mites
  • Compare subcutaneous to sublingual tablet immunotherapy in relief of house dust mite allergy and asthma from the latest published data
  • Be able to employ shared decision making for house dust mite immunotherapy your practice setting
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. The ACCME defines a "commercial interest" as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified conflicts of interest must be resolved, and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

All identified conflicts of interest have been resolved.

Eli Meltzer, MD, FACAAI

ALK: Consultant/Speaker Honorarium, Consulting fee

AstraZeneca: Consultant; Consulting fee

Boehringer-Ingelheim: Consultant; Consulting fee

GlaxoSmithKline: Consultant; Consulting fee

Glenmark: Consultant/Speaker; Consulting Fee, Honorarium

GossamerBio: Consultant; Consulting Fee

Merck: Consultant; Consulting Fee

Mylan: Consultant; Consulting Fee

Regeneron/Sanofi: Consultant, Speaker; Consulting Fee, Honorarium

 

John Oppenheimer, MD, FACAAI

Teva: Consultant; Consulting fee

DBV Technologies: Consultant; Consulting fee

GlaxoSmithKline: Consultant; Consulting fee

MedImmune: Adjudication; Consulting fee

Sanofi: Consultant; Consulting fee

Up to Date: Reviewer; Honorarium

Medscape: Senior Editor; Honorarium

 

Michael Blaiss, MD, FACAAI

ALK: Consultant; Consulting fee

Boston Scientific: Consultant; Consulting fee

Pfizer: Consultant; Consulting fee

PMD Healthcare: Consultant; Consulting fee

RX Bands: Consultant; Consulting fee

Stallergenes: Consultant; Consulting fee

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
05/09/2019
Course expires: 
05/08/2022
Event starts: 
05/09/2019 - 7:00pm
Event ends: 
05/09/2019 - 8:00pm
Rating: 
0

Eli Meltzer, MD, FACAAI

ALK: Consultant/Speaker Honorarium, Consulting fee

AstraZeneca: Consultant; Consulting fee

Boehringer-Ingelheim: Consultant; Consulting fee

GlaxoSmithKline: Consultant; Consulting fee

Glenmark: Consultant/Speaker; Consulting Fee, Honorarium

GossamerBio: Consultant; Consulting Fee

Merck: Consultant; Consulting Fee

Mylan: Consultant; Consulting Fee

Regeneron/Sanofi: Consultant, Speaker; Consulting Fee, Honorarium

 

John Oppenheimer, MD, FACAAI

Teva: Consultant; Consulting fee

DBV Technologies: Consultant; Consulting fee

GlaxoSmithKline: Consultant; Consulting fee

MedImmune: Adjudication; Consulting fee

Sanofi: Consultant; Consulting fee

Up to Date: Reviewer; Honorarium

Medscape: Senior Editor; Honorarium

 

Michael Blaiss, MD, FACAAI

ALK: Consultant; Consulting fee

Boston Scientific: Consultant; Consulting fee

Pfizer: Consultant; Consulting fee

PMD Healthcare: Consultant; Consulting fee

RX Bands: Consultant; Consulting fee

Stallergenes: Consultant; Consulting fee

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or create an account to take this course.